Boule Diagnostics today launches new veterinary 5-part hematology solution in Europe

Boule Diagnostics is today launching a new 5-part veterinary solution for cost-effective diagnostics for the European market, the H50V. It is equipped with 13 predefined animal profiles and over 30 analyzed parameters, making it a flexible system that meets the requirements of many types of veterinary clinics and laboratories. The H50V features a 5-part white blood cell (WBC) differential with results delivered within one (1) minute. It is compact and easy to use with intuitive touch screen interface and comes with a built-in mixer.

“The rise in companion animals is driving the demand for veterinary diagnostics. This week, we launched the H50V solution, and we have already dispatched the first batch of instruments to our customers. The H50V, along with our existing Exigo H400 and Exigo C200 solutions, strengthens our veterinary portfolio. This in combination with our expanded sales footprint through FujiFilm Europe create new opportunities for Boule to grow the veterinary business,” says CEO and Group President, Jesper Söderqvist.

For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.

The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on June 29, 2023.

Boule Diagnostics Expanded Veterinary offering 230629

  • Subscribe to our news